Fig. 4From: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancerCost-effectiveness acceptability curve for probabilistic sensitivity analyses. Plot of the probability of cost-effectiveness for TAS-102 monotherapy and TAS-102 plus bevacizumab combination therapy versus different willingness-to-pay valuesBack to article page